Monthly shot may boost opioid treatment success in hospitals

NCT ID NCT04345718

Completed Disease control Sponsor: Gavin Bart Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a once-monthly injection of extended-release buprenorphine helps hospitalized patients with moderate to severe opioid use disorder stay in treatment better than usual care (like daily pills or methadone). Over 300 adults were randomly assigned to receive either the injection or standard medication before leaving the hospital. Researchers tracked how many were still engaged in treatment 34 days later, with follow-ups at 90 and 180 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: extended-release buprenorphine
What this could lead to: If successful, this could show that a monthly injection of buprenorphine helps more people stay in treatment for opioid use disorder compared to daily pills or other standard options.
What could go wrong: This is a completed Phase 2/3 trial, but results may not apply to all patients or settings. Extended-release buprenorphine can have side effects like injection site reactions or withdrawal symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPIOID USE DISORDER, MODERATE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

follicular lymphoma opiate dependence substance-related disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OPIOID USE DISORDER, MODERATE OPIOID USE DISORDER, SEVERE SUBSTANCE USE DISORDER

Contacts and locations

Locations

Boston University

Boston, Massachusetts, 02118, United States
Hennepin Healthcare Research Institute

Minneapolis, Minnesota, 55404, United States
Johns Hopkins Bayview Medical Center

Baltimore, Maryland, 21224, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, 15213, United States
Yale New Haven Hospital

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.